Nationwide multicenter survey on the pathophysiology of hospital-acquired pneumonia and the use of first-line antibiotics in Japan: Evaluation of clinical position of meropenem in the initial therapy of hospital-acquired pneumonia

Japanese Journal of Chemotherapy

Volumn 54, Issue 5, 2006, Pages 453-464

  Kohno, Shigeru ^a   Watanabe, Akira ^b   Matsushima, Toshiharu ^c  

^a NAGASAKI UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Kurashiki Daiichi Hospital   (Japan)

Author keywords

Guideline; Hospital acquired pneumonia; Meropenem

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; CARBAPENEM DERIVATIVE; CLINDAMYCIN; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; MEROPENEM; NITROGEN; POTASSIUM; TETRACYCLINE DERIVATIVE; UREA;

ANEMIA; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD DISEASE; CLINICAL PROTOCOL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG USE; GASTROINTESTINAL DISEASE; HEALTH SURVEY; HEPATOBILIARY DISEASE; HOSPITAL INFECTION; HUMAN; HYPOCALCIURIA; HYPONATREMIA; JAPAN; KIDNEY DISEASE; LIVER DYSFUNCTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PATHOPHYSIOLOGY; PNEUMONIA; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PRURITUS; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SKIN DISEASE; UREA NITROGEN BLOOD LEVEL; URINARY TRACT DISEASE;

EID: 33749334464     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. American Thoracic Society: Hospital-acquired pneumonia in adults; diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement. Am J Respir Crit Care Med 1996; 153:1711-25
2. Japanese source. 2002
3. Japanese source. Infect Contr 2000; 9: 1421-8
4. Ohi H, Yanagihara K, Miyazaki Y, et al: Hospital-acquired pneumonia in general wards of a Japanese tertiary hospital. Respirology 2004; 9: 120-4
5. Japanese source. 2004.
6. Japanese source. Jap J Antibiot 2004; 57:70-104
7. Watanabe A, Tokue Y, Kikuchi T, et al: Antibacterial activity of carbapenems against clinically isolated respiratory bacterial pathogens in Japan between 2003 and 2004. Int J Antimicrob Agents 2005; 26:420-3
8. Japanese source. 2005; 43:230
9. Japanese source. 2004
10. American Thoracic Society/Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416
11. Turnidge J D: The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27:10-22
12. Craven D E, Steger K A: Epidemiology of nosocomial pneumonia: new perspectives on an old disease. Chest 1995; 108 (2 Suppl): 1s-16s
13. Craven D E, Barber T W, Steger K A, et al: Nosocomial pneumonia in the 1990s: Update of epidemiology and risk factors. Semin Respir Infect 1990; 5: 157-72
14. Craven D E, Steger K A: Nosocomial pneumonia in mechanically ventilated adult patients: epidemiology and prevention in 1996. Semin Respir Infect 1996; 11: 32-53
15. Berman S J, Fogarty C M, Fabian T, et al: Meropenem monotherapy for the treatment of hospital-acquired pneumonia: Results of a multicenter trial. J Chemother 2004; 16:362-71
16. Santos S S, Machado F R, Kiffer C R V, et al: Treatment of nosocomial pneumonia: An experience with meropenem. Braz J Infect Dis 2001; 5:124-9
17. Sieger B, Berman S J, Geckler R W, et al: Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomized study. Crit Care Med 1997; 25:1663-70
18. Colardyn F, Faulkner K L on behalf of the meropenem serious infection study group: Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996; 38:523-37
19. Garau J, Blanquer J, Cobo L, et al: Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997; 16:789-96
20. Lerma F A, on behalf of the serious infection study group: Efficacy of meropenem, as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13:70-81
21. Verweast C, on behalf of the Belgian multicenter study group: Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000; 6:294-302
22. Mouton Y J, Beuscart C, the Meropenem Study Group: Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995; 36 (Suppl A):145-56
23. Hartenauer U, Kljucar S, Bender H-J, et al: Meropenem versus imipenem/ cilastatin for the treatment of serious bacterial infections at ICU. Antiinfect Drugs Chemother 1997; 15:65-70
24. Japanese source. 2004.